You are working the night shift in the Emergency Department. A patient arrives accompanied by a friend. The patient has had a drastic change in mental status, has become very agitated and seems to be having some hallucinations and is very disorientated. She is sweating profusely and has a slight tremor along with some scary muscle spasms. Upon further questioning you discover she has just started on fluoxetine (Prozac). She denies any alcohol intake or any other medications, recreationally or prescribed. She has had nothing different in her diet and has not traveled anywhere except to work, shopping and home. Her friend says she was with her when she took her first dose which was about 24 hours ago. What are your thoughts about what is happening and what is the appropriate action to be taken?
Patient is most likely experiencing Serotonin Syndrome. Add an MAOI and monitor patient
Patient most likely experiencing Serotonin Syndrome. Decrease the dose of the Prozac
Patient is experiencing an allergic reaction. Treat with epinephrine and diphenhydramine.
Patient is experiencing Serotonin Syndrome. Stop the medication immediately
The Correct Answer is D
Acute changes in mental status accompanied by autonomic instability and neuromuscular abnormalities after initiation of serotonergic medications suggest a life-threatening condition, serotonin toxicity. Serotonin syndrome occurs due to excessive serotonergic activity in the central nervous system, often shortly after starting or increasing doses of SSRIs. Clinical features include agitation, confusion, hyperthermia, tremors, muscle rigidity, and autonomic dysregulation such as diaphoresis. Rapid recognition and immediate discontinuation of the causative agent are critical to prevent progression to severe toxicity or death.
Rationale:
A. Adding an MAOI is dangerous and would significantly worsen the condition. Monoamine oxidase inhibitors further increase serotonin levels and can precipitate severe, potentially fatal serotonin toxicity when combined with SSRIs. This contradicts safe management principles and would intensify symptoms such as hyperthermia, rigidity, and autonomic instability.
B. Decreasing the dose of fluoxetine is inappropriate in an acute toxic reaction. Serotonin syndrome is not dose-managed but requires immediate cessation of the offending agent. Dose reduction would still allow ongoing serotonergic excess and could delay critical intervention, increasing the risk of complications such as seizures or organ failure.
C. An allergic reaction is unlikely because the symptoms described are not consistent with histamine-mediated hypersensitivity. There is no evidence of urticaria, airway swelling, or anaphylaxis. Instead, the combination of agitation, tremor, hyperreflexia, and muscle spasms strongly indicates a toxic serotonergic state rather than an immunologic reaction.
D. Immediate discontinuation of Fluoxetine is the priority intervention in serotonin syndrome. Removing the serotonergic agent stops further accumulation of serotonin activity in the central nervous system. Supportive care, sedation, and close monitoring are also required to stabilize autonomic and neuromuscular symptoms and prevent progression to severe complications.
Nursing Test Bank
Naxlex Comprehensive Predictor Exams
Related Questions
Correct Answer is D
Explanation
Opioid analgesics are classified based on their activity at opioid receptors as full agonists, partial agonists, or agonist-antagonists. Agonist-antagonist opioids stimulate certain receptors while blocking others, producing analgesia with a lower risk of respiratory depression compared to full agonists. These drugs are often used in specific pain management situations or to reduce abuse potential. Understanding these classifications is essential for safe opioid selection and preventing adverse effects.
Rationale:
A. Nalbuphine is an agonist-antagonist opioid that acts as a kappa receptor agonist and a mu receptor antagonist. This dual action provides analgesia while limiting the degree of respiratory depression and euphoria. It is commonly used for moderate to severe pain and is known for having a ceiling effect on respiratory depression.
B. Pentazocine is another agonist-antagonist opioid that stimulates kappa receptors and partially blocks mu receptors. It produces analgesia but may also cause side effects such as dysphoria and hallucinations due to its receptor profile. It is classified clearly within the agonist-antagonist group.
C. Buprenorphine functions as a partial agonist at mu receptors and an antagonist at kappa receptors, placing it within the agonist-antagonist category. It is used for both pain management and opioid dependence treatment due to its ceiling effect on respiratory depression and lower abuse potential.
D. Morphine is a full opioid agonist that strongly activates mu receptors without antagonist activity. It produces potent analgesia but carries a higher risk of respiratory depression, dependence, and euphoria. Because it lacks antagonist properties, it does not belong to the agonist-antagonist class.
Correct Answer is D
Explanation
Second-generation antipsychotics (atypical antipsychotics) are medications that primarily act on dopamine and serotonin receptors to manage psychotic disorders and mood instability. Some agents in this class are also approved for bipolar disorder and certain tic disorders due to their dopamine-modulating effects. These drugs differ in receptor affinity profiles, which influences their clinical uses and side effect burden.
Rationale:
A. Quetiapine (Seroquel) is a second-generation antipsychotic commonly used for schizophrenia, bipolar disorder, and major depressive disorder adjunct therapy. It has strong sedative effects due to histamine receptor blockade but is not a first-line agent for Tourette syndrome. Its primary use is mood stabilization and psychosis rather than tic suppression.
B. Risperidone (Risperdal) is an atypical antipsychotic used for schizophrenia, bipolar disorder, and irritability associated with autism spectrum disorder. It is also used in some cases of Tourette syndrome, but it has a higher risk of extrapyramidal symptoms at higher doses. Despite this, it is not the best match for the combined indication profile.
C. Olanzapine (Zyprexa) is a second-generation antipsychotic used for schizophrenia and bipolar disorder, particularly for acute manic episodes. It is associated with significant metabolic side effects such as weight gain and hyperglycemia. It is not commonly indicated for Tourette syndrome, limiting its fit for the combined clinical scenario.
D. Aripiprazole (Abilify) is a second-generation antipsychotic that acts as a partial dopamine agonist, which helps stabilize dopamine activity rather than fully blocking it. It is approved for schizophrenia, bipolar disorder, and Tourette syndrome due to its effectiveness in reducing tics and mood symptoms.
Whether you are a student looking to ace your exams or a practicing nurse seeking to enhance your expertise , our nursing education contents will empower you with the confidence and competence to make a difference in the lives of patients and become a respected leader in the healthcare field.
Visit Naxlex, invest in your future and unlock endless possibilities with our unparalleled nursing education contents today
Report Wrong Answer on the Current Question
Do you disagree with the answer? If yes, what is your expected answer? Explain.
Kindly be descriptive with the issue you are facing.